Amprion

EQS-News: Amprion GmbH: Amprion invests record amount in accelerated grid expansion

Retrieved on: 
Saturday, April 15, 2023
Acceleration, Electricity, RAB, Government, EBITDA, Investment, FTE, CFO, Growth, Environment, Security (finance), Renewable energy, Amprion

The transmission system operator Amprion is accelerating grid expansion and continues to grow.

Key Points: 
  • The transmission system operator Amprion is accelerating grid expansion and continues to grow.
  • With its investments, the company addresses the accelerated expansion of renewable energy and the transformation of the energy system.
  • In the 2022 financial year, Amprion invested a record amount of 1.5 billion euros in the expansion and conversion of the grid infrastructure.
  • The investments realised in 2022 continue to focus on the expansion of the grid, more than 80 percent are expansion investments.

EQS-News: FRIEDRICH VORWERK concludes framework contract with TenneT for the execution of HDD drilling for offshore connection lines and receives first call order in the high double-digit million range

Retrieved on: 
Saturday, April 15, 2023
Wind, ISIN, Tostedt, Farm, IPA, HDD, Schleswig-Holstein, TenneT, Island, Amprion, Natural gas

Bohlen & Doyen constitutes part of a joint venture with equal rights, which also includes the companies Matthäi and Beermann.

Key Points: 
  • Bohlen & Doyen constitutes part of a joint venture with equal rights, which also includes the companies Matthäi and Beermann.
  • Shortly after signing, TenneT already ordered the first services from the framework contract.
  • These include a series of drillings for the grid connection of the offshore systems BorWin6, Heide1 and Baltrum1-5 in Schleswig-Holstein and Lower Saxony.
  • The total value of the orders is well into the three-digit million range, in which Bohlen & Doyen will have a share in the high double-digit million range.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

MICHAEL J. FOX FOUNDATION ANNOUNCES SIGNIFICANT BREAKTHROUGH IN SEARCH FOR PARKINSON'S BIOMARKER

Retrieved on: 
Wednesday, April 12, 2023
Insurance, PD, RBD, GBA, The Michael J. Fox Foundation, Pathology, Doctor of Philosophy, Dementia, Alzheimer's disease, Dream, Patient, MD, Three-body problem, MJFF, Synuclein, Risk, Anosmia, Disease, Science, DaT scan, University, Lancet Neurology, University of Texas at Austin, Mutation, Research, Parkinson's disease, Data, Medicine, Alpha-synuclein, Biology, Diagnosis, LRRK2, DLB, Biomarker, Sleep disorder, DAT, Edmond, Connie, The Lancet, Amprion, Drug development, Multiple system atrophy, Rapid eye movement sleep behavior disorder, Neurodegenerative disease, ASAP, Movement, MSA, Physician, REM, Medical imaging, Pharmaceutical industry, Dietary supplement, Nursing

Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.

Key Points: 
  • Fox Foundation for Parkinson's Research (MJFF), confirms the most significant breakthrough yet in the search for a Parkinson's biomarker: a biological test for Parkinson's disease that demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise.
  • "Using αSyn-SAA, we are already unlocking new understanding of Parkinson's, which will transform every aspect of drug development and ultimately clinical care.
  • Only about 30 percent of at-risk individuals with a positive seed amplification assay result also had significant dopamine loss.
  • In addition to ASAP, PPMI is supported by the Edmond J. Safra Foundation, the Farmer Family Foundation and Connie and Steve Ballmer.

EQS-News: Amprion GmbH: Amprion annual results conference call for investors and analysts

Retrieved on: 
Friday, March 31, 2023
Annual report, Amprion, Security (finance)

Amprion GmbH will publish its annual report for the financial year 2022 on Thursday, 13th April 2023.

Key Points: 
  • Amprion GmbH will publish its annual report for the financial year 2022 on Thursday, 13th April 2023.
  • On this occasion we cordially invite you to our:
    In this call, Peter Rüth – Chief Financial Officer – will present the annual results for the financial year 2022 and will provide further insights into the business development.
  • The conference call will be held in English.
  • A recording of the call will be made available after the event on our corporate website.

Amprion showcases SYNTap® Biomarker Test at AD/PD™ 2023 International Conference

Retrieved on: 
Monday, March 27, 2023
Alpha-synuclein, Myenteric plexus, LDT, PD, Multiple system atrophy, Doctor of Philosophy, The Michael J. Fox Foundation, DSM-IV codes, Approximation error, Lewy, Cerebrospinal fluid, Lewy body dementias, Dementia, Parkinson's disease, International Conference on Emerging Infectious Diseases, MJFF, MSA, Patient, SAN, Medicine, Laboratory developed test, Exhibition, Diagnosis, CSF, AD, Research, LBD, Synucleinopathy, Conference, Amprion, Medical imaging, Alzheimer's disease, Disease, MD

SAN DIEGO, March 27, 2023 /PRNewswire/ -- Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden on March 28-April 1. Amprion's findings will be highlighted in one oral presentation on Friday, March 31st 16:50 CET in hall G4 during the Alpha-Synuclein, PD Mechanistic Aspects Symposium, and in three posters located within the exhibition hall. Please see below for more information. Amprion's SYNTap Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies.

Key Points: 
  • Amprion's SYNTap Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies.
  • "It is estimated that around 44 million people worldwide are living with Alzheimer's disease or a related form of dementia.
  • "Amprion is committed to positively impacting brain disease diagnosis, which will help accelerate life-saving drug development for patients suffering from these diseases.
  • SYNTap will also be presented in the context of three posters, located in the Exhibition Area for all conference days that the Exhibition is open:

EQS-News: Amprion GmbH: Sustainable value chain: Amprion decides to reduce Scope-3-emissions

Retrieved on: 
Saturday, March 11, 2023
Science Based Targets initiative, Travel, Climate, Science, Carbon accounting, Environment, Amprion, Green Deal, CO2, Electricity, Renewable energy

The transmission system operator Amprion has committed to reducing emissions along its value chain by almost 60 percent by 2032.

Key Points: 
  • The transmission system operator Amprion has committed to reducing emissions along its value chain by almost 60 percent by 2032.
  • Amprion is underlining its claim to operate sustainably in the expansion and conversion of the electricity transmission network.
  • I am pleased that we have also committed to an ambitious but realistic CO2 reduction path for our value chain.
  • For Amprion, this is a further step on the path to climate neutrality for our organisation," said Amprion CEO, Dr. Hans-Jürgen Brick.

EQS-News: Amprion GmbH: Amprion increases syndicated loan agreement by €500 million

Retrieved on: 
Thursday, February 23, 2023
SEB, DZ Bank, Commerzbank, Acceleration, Investment, ING, UniCredit, Bayerische Landesbank, Security (finance), Bank, Amprion

The transmission system operator Amprion has successfully increased the volume of its existing syndicated loan agreement by using a contractually agreed increase option.

Key Points: 
  • The transmission system operator Amprion has successfully increased the volume of its existing syndicated loan agreement by using a contractually agreed increase option.
  • The credit line has been increased by €500 million to a total of €2,000 million.
  • By stepping up the syndicated loan agreement, Amprion increases its flexibility for short-term financing and responds to the significant rise in investments in the short and medium term due to the acceleration of the grid expansion.
  • Peter Rüth, Chief Financial Officer of Amprion: "The syndicated loan agreement with our eight banking partners is the basis for our bridge-to-bond financing strategy.

EQS-News: Amprion GmbH: Amprion awarded as ESG top performer

Retrieved on: 
Thursday, February 2, 2023
Hang Seng China A Industry Top Index, Climate, ESG, Risk, Sustainalytics, Lithium, Amprion

Sustainalytics has included the transmission system operator Amprion in its list of “2023 top-rated ESG companies“.

Key Points: 
  • Sustainalytics has included the transmission system operator Amprion in its list of “2023 top-rated ESG companies“.
  • The rating agency, specialised in sustainability, thereby awards the “ESG Industry Top Rated“-label and recognises Amprion’s work in the field of sustainability.
  • As a result of the annual assessment, Amprion was included in the list of “2023 top-rated ESG companies“ by Sustainalytics and receives the “ESG Industry Top Rated“-award.
  • Peter Rüth, Chief Financial Officer of Amprion comments: “Receiving the first ESG risk rating from Sustainalytics last year was an important milestone for Amprion.

EQS-News: Amprion awards converter stations to Siemens Energy und Dragados Offshore – LanWin1 and LanWin3 to be greatly accelerated

Retrieved on: 
Sunday, January 22, 2023
Government, 2018 German government crisis, Wind, Acceleration, Climate, Federation, Gesellschaft mit beschränkter Haftung, Electricity, Maintenance, Farm, Siemens Energy, Amprion, Renewable energy

Amprion Offshore GmbH has awarded Siemens Energy and Dragados Offshore to build the converter stations for the LanWin1 and LanWin3 offshore grid connection systems.

Key Points: 
  • Amprion Offshore GmbH has awarded Siemens Energy and Dragados Offshore to build the converter stations for the LanWin1 and LanWin3 offshore grid connection systems.
  • The plans provide for LanWin1 to go into operation as early as 2029 instead of 2031 and for LanWin3 as early as 2030 instead of 2033.
  • That is why we are very pleased to have won two partners in Siemens Energy and Dragados Offshore who can implement our converters quickly and reliably," says Peter Barth, managing director of Amprion Offshore GmbH.
  • With the 2 gigawatt converters, Amprion is entering the new performance class of offshore grid connection systems.